Skip to main content
Top
Published in: Inflammation 4/2012

01-08-2012

Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells

Authors: Xin Mao, Xiaoyun Pan, Xiaochun Peng, Tao Cheng, Xianlong Zhang

Published in: Inflammation | Issue 4/2012

Login to get access

Abstract

Wear particle-induced inflammatory osteolysis is the major cause of aseptic loosening after total joint replacement. The predominant cell type within periprosthetic tissues is macrophages. We investigate the anti-inflammatory effects of the proteasome inhibitor bortezomib (Bzb) on murine macrophage-like RAW 264.7 cells stimulated with titanium (Ti) particles. RAW 264.7 cells were cultured with 1 nM Bzb and 0.1 mg/ml Ti particles for 48 h; cells without Ti and Bzb or without Bzb were used as negative and loading controls. Results showed that the expression of inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10), chemokines [monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1α)], and inflammatory enzymes [inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2)] increased in RAW 264.7 cells cultured with Ti. Bzb treatment significantly reduced the expression of TNF-α, IL-1β, IL-6, MCP-1, MIP-1α, iNOS, and COX-2 and induced the expression of IL-10 in a time-dependent manner. These results suggest that Bzb inhibits Ti-induced inflammation in macrophages, and provide a promising therapeutic target for treating or preventing aseptic loosening.
Literature
1.
go back to reference Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271–1286.PubMedCrossRef Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271–1286.PubMedCrossRef
2.
go back to reference Berry, D., W. Harmsen, M. Cabanela, and B. Morrey. 2002. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components. The Journal of Bone and Joint Surgery. American Volume 84(2): 171–177.PubMed Berry, D., W. Harmsen, M. Cabanela, and B. Morrey. 2002. Twenty-five-year survivorship of two thousand consecutive primary Charnley total hip replacements: Factors affecting survivorship of acetabular and femoral components. The Journal of Bone and Joint Surgery. American Volume 84(2): 171–177.PubMed
3.
go back to reference Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177–197.PubMedCrossRef Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177–197.PubMedCrossRef
4.
go back to reference Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043–1051.PubMedCrossRef Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043–1051.PubMedCrossRef
5.
go back to reference Sabokbar, A., O. Kudo, and N. Athanasou. 2003. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. Journal of Orthopaedic Research 21(1): 73–80.PubMedCrossRef Sabokbar, A., O. Kudo, and N. Athanasou. 2003. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. Journal of Orthopaedic Research 21(1): 73–80.PubMedCrossRef
6.
go back to reference Wang, C.T., Y.T. Lin, B.L. Chiang, S.S. Lee, and S.M. Hou. 2010. Over-expression of receptor activator of nuclear factor-[kappa] B ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 31(1): 77–82.PubMedCrossRef Wang, C.T., Y.T. Lin, B.L. Chiang, S.S. Lee, and S.M. Hou. 2010. Over-expression of receptor activator of nuclear factor-[kappa] B ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 31(1): 77–82.PubMedCrossRef
7.
go back to reference Im, G.I., and J.D. Han. 2001. Suppressive effects of interleukin‐4 and interleukin‐10 on the production of proinflammatory cytokines induced by titanium‐alloy particles. Journal of Biomedical Materials Research 58(5): 531–536.PubMedCrossRef Im, G.I., and J.D. Han. 2001. Suppressive effects of interleukin‐4 and interleukin‐10 on the production of proinflammatory cytokines induced by titanium‐alloy particles. Journal of Biomedical Materials Research 58(5): 531–536.PubMedCrossRef
8.
go back to reference Sabat, R., G. Grütz, K. Warszawska, S. Kirsch, E. Witte, K. Wolk, and J. Geginat. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21(5): 331–344.CrossRef Sabat, R., G. Grütz, K. Warszawska, S. Kirsch, E. Witte, K. Wolk, and J. Geginat. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21(5): 331–344.CrossRef
9.
go back to reference Fritz, E.A., T.T. Glant, C. Vermes, J.J. Jacobs, and K.A. Roebuck. 2006. Chemokine gene activation in human bone marrow‐derived osteoblasts following exposure to particulate wear debris. Journal of Biomedical Materials Research. Part A 77(1): 192–201.PubMedCrossRef Fritz, E.A., T.T. Glant, C. Vermes, J.J. Jacobs, and K.A. Roebuck. 2006. Chemokine gene activation in human bone marrow‐derived osteoblasts following exposure to particulate wear debris. Journal of Biomedical Materials Research. Part A 77(1): 192–201.PubMedCrossRef
10.
go back to reference Huang, Z., T. Ma, P.G. Ren, R.L. Smith, and S.B. Goodman. 2010. Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. Journal of Biomedical Materials Research. Part A 94(4): 1264–1269.PubMed Huang, Z., T. Ma, P.G. Ren, R.L. Smith, and S.B. Goodman. 2010. Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. Journal of Biomedical Materials Research. Part A 94(4): 1264–1269.PubMed
11.
go back to reference Hukkanen, M., S. Corbett, J. Batten, Y. Konttinen, I. McCarthy, J. Maclouf, S. Santavirta, S. Hughes, and J. Polak. 1997. Aseptic loosening of total hip replacement: Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. Journal of Bone and Joint Surgery 79(3): 467–474.PubMedCrossRef Hukkanen, M., S. Corbett, J. Batten, Y. Konttinen, I. McCarthy, J. Maclouf, S. Santavirta, S. Hughes, and J. Polak. 1997. Aseptic loosening of total hip replacement: Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. Journal of Bone and Joint Surgery 79(3): 467–474.PubMedCrossRef
12.
go back to reference Elliott, P.J., and J.S. Ross. 2001. The proteasome. American Journal of Clinical Pathology 116(5): 637–646.PubMedCrossRef Elliott, P.J., and J.S. Ross. 2001. The proteasome. American Journal of Clinical Pathology 116(5): 637–646.PubMedCrossRef
13.
go back to reference Bedford, L., S. Paine, P.W. Sheppard, R.J. Mayer, and J. Roelofs. 2010. Assembly, structure, and function of the 26S proteasome. Trends in Cell Biology 20(7): 391–401.PubMedCrossRef Bedford, L., S. Paine, P.W. Sheppard, R.J. Mayer, and J. Roelofs. 2010. Assembly, structure, and function of the 26S proteasome. Trends in Cell Biology 20(7): 391–401.PubMedCrossRef
14.
go back to reference Elliott, P.J., T.M. Zollner, and W.H. Boehncke. 2003. Proteasome inhibition: A new anti-inflammatory strategy. Journal of Molecular Medicine 81(4): 235–245.PubMed Elliott, P.J., T.M. Zollner, and W.H. Boehncke. 2003. Proteasome inhibition: A new anti-inflammatory strategy. Journal of Molecular Medicine 81(4): 235–245.PubMed
15.
go back to reference Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348(26): 2609–2617.PubMedCrossRef Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348(26): 2609–2617.PubMedCrossRef
16.
go back to reference Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant‐induced arthritis in rats. Arthritis and Rheumatism 62(11): 3277–3288.PubMedCrossRef Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant‐induced arthritis in rats. Arthritis and Rheumatism 62(11): 3277–3288.PubMedCrossRef
17.
go back to reference Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761–1767.PubMedCrossRef Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761–1767.PubMedCrossRef
18.
go back to reference Rakshit, D., K. Ly, T. Sengupta, B. Nestor, T. Sculco, L. Ivashkiv, and P. Purdue. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. The Journal of Bone and Joint Surgery. American Volume 88(4): 788–799.PubMedCrossRef Rakshit, D., K. Ly, T. Sengupta, B. Nestor, T. Sculco, L. Ivashkiv, and P. Purdue. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. The Journal of Bone and Joint Surgery. American Volume 88(4): 788–799.PubMedCrossRef
19.
go back to reference Sethi, R.K., M.J. Neavyn, H.E. Rubash, and A.S. Shanbhag. 2003. Macrophage response to cross-linked and conventional UHMWPE. Biomaterials 24(15): 2561–2573.PubMedCrossRef Sethi, R.K., M.J. Neavyn, H.E. Rubash, and A.S. Shanbhag. 2003. Macrophage response to cross-linked and conventional UHMWPE. Biomaterials 24(15): 2561–2573.PubMedCrossRef
20.
go back to reference Lee, S., C. Woo, J. Chang, and J. Kim. 2003. Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles. Cellular Signalling 15(3): 339–345.PubMedCrossRef Lee, S., C. Woo, J. Chang, and J. Kim. 2003. Roles of Rac and cytosolic phospholipase A2 in the intracellular signalling in response to titanium particles. Cellular Signalling 15(3): 339–345.PubMedCrossRef
21.
go back to reference Möller, B., and P.M. Villiger. 2006. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Seminars in Immunopathology 27(4): 391–408.PubMedCrossRef Möller, B., and P.M. Villiger. 2006. Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseases. Springer Seminars in Immunopathology 27(4): 391–408.PubMedCrossRef
22.
go back to reference Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist–deficient mice. The Journal of Experimental Medicine 191(2): 313–320.PubMedCrossRef Horai, R., S. Saijo, H. Tanioka, S. Nakae, K. Sudo, A. Okahara, T. Ikuse, M. Asano, and Y. Iwakura. 2000. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist–deficient mice. The Journal of Experimental Medicine 191(2): 313–320.PubMedCrossRef
23.
go back to reference Caicedo, M., J.J. Jacobs, and N.J. Hallab. 2010. Inflammatory bone loss in joint replacements: The mechanisms. Journal Musculoskeletal Medicine 27: 209–216. Caicedo, M., J.J. Jacobs, and N.J. Hallab. 2010. Inflammatory bone loss in joint replacements: The mechanisms. Journal Musculoskeletal Medicine 27: 209–216.
24.
25.
go back to reference Suzuki, Y., T. Nishiyama, K. Hasuda, T. Fujishiro, T. Niikura, S. Hayashi, S. Hashimoto, and M. Kurosaka. 2007. Effect of etidronate on COX-2 expression and PGE 2 production in macrophage-like RAW 264.7 cells stimulated by titanium particles. Journal of Orthopaedic Science 12(6): 568–577.PubMedCrossRef Suzuki, Y., T. Nishiyama, K. Hasuda, T. Fujishiro, T. Niikura, S. Hayashi, S. Hashimoto, and M. Kurosaka. 2007. Effect of etidronate on COX-2 expression and PGE 2 production in macrophage-like RAW 264.7 cells stimulated by titanium particles. Journal of Orthopaedic Science 12(6): 568–577.PubMedCrossRef
26.
go back to reference Ragab, A.A., J.L. Nalepka, Y. Bi, and E.M. Greenfield. 2002. Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. American Journal of Physiology. Cell Physiology 283(3): C679–C687.PubMed Ragab, A.A., J.L. Nalepka, Y. Bi, and E.M. Greenfield. 2002. Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. American Journal of Physiology. Cell Physiology 283(3): C679–C687.PubMed
27.
go back to reference Goodman, S.B., and T. Ma. 2010. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 31(19): 5045–5050.PubMedCrossRef Goodman, S.B., and T. Ma. 2010. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 31(19): 5045–5050.PubMedCrossRef
28.
go back to reference Harris, S.G., J. Padilla, L. Koumas, D. Ray, and R.P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends in Immunology 23(3): 144–150.PubMedCrossRef Harris, S.G., J. Padilla, L. Koumas, D. Ray, and R.P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends in Immunology 23(3): 144–150.PubMedCrossRef
29.
go back to reference Steeve, K.T., P. Marc, T. Sandrine, H. Dominique, and F. Yannick. 2004. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews 15(1): 49–60.CrossRef Steeve, K.T., P. Marc, T. Sandrine, H. Dominique, and F. Yannick. 2004. IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine & Growth Factor Reviews 15(1): 49–60.CrossRef
30.
go back to reference Krakauer, T. 2004. Molecular therapeutic targets in inflammation: Cyclooxygenase and NF-kappaB. Current Drug Targets. Inflammation and Allergy 3(3): 317–324.PubMedCrossRef Krakauer, T. 2004. Molecular therapeutic targets in inflammation: Cyclooxygenase and NF-kappaB. Current Drug Targets. Inflammation and Allergy 3(3): 317–324.PubMedCrossRef
31.
go back to reference Smallie, T., G. Ricchetti, N.J. Horwood, M. Feldmann, A.R. Clark, and L.M. Williams. 2010. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. The Journal of Experimental Medicine 207(10): 2081–2088.PubMedCrossRef Smallie, T., G. Ricchetti, N.J. Horwood, M. Feldmann, A.R. Clark, and L.M. Williams. 2010. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. The Journal of Experimental Medicine 207(10): 2081–2088.PubMedCrossRef
32.
go back to reference Lentsch, A.B., T.P. Shanley, V. Sarma, and P.A. Ward. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. The Journal of Clinical Investigation 100(10): 2443–2448.PubMedCrossRef Lentsch, A.B., T.P. Shanley, V. Sarma, and P.A. Ward. 1997. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. The Journal of Clinical Investigation 100(10): 2443–2448.PubMedCrossRef
33.
go back to reference Su, Y.W., W.F. Chiou, S.H. Chao, M.H. Lee, C.C. Chen, and Y.C. Tsai. 2011. Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-kappaB and AP-1 signaling pathways. International Immunopharmacology 11(9): 1166–1172.PubMedCrossRef Su, Y.W., W.F. Chiou, S.H. Chao, M.H. Lee, C.C. Chen, and Y.C. Tsai. 2011. Ligustilide prevents LPS-induced iNOS expression in RAW 264.7 macrophages by preventing ROS production and down-regulating the MAPK, NF-kappaB and AP-1 signaling pathways. International Immunopharmacology 11(9): 1166–1172.PubMedCrossRef
34.
go back to reference Goldberg, A. 2007. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochemical Society Transactions 35: 12–17.PubMedCrossRef Goldberg, A. 2007. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochemical Society Transactions 35: 12–17.PubMedCrossRef
Metadata
Title
Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells
Authors
Xin Mao
Xiaoyun Pan
Xiaochun Peng
Tao Cheng
Xianlong Zhang
Publication date
01-08-2012
Publisher
Springer US
Published in
Inflammation / Issue 4/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-012-9454-5

Other articles of this Issue 4/2012

Inflammation 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.